Synchronous and Metachronous Breast and Ovarian Cancer: Experience From Two Large Cancer Center

We aimed to evaluate the clinico-pathological characteristics and survival outcomes of patients with synchronous or metachronous breast cancer (BC) and ovarian cancer (OC). Patients with synchronous or metachronous BC and OC were retrospectively identified at two large cancer centers. Clinico-pathological characteristics, and follow-up data were gathered. Patients were classified according to the first cancer diagnosis in the following groups: Breast Cancer , Ovarian Cancer , Synchronous Breast and Ovarian Cancer. Overall survival (OS) was calculated as the time interval between each cancer diagnosis to death or last follow-up. Overall, 270 patients were included: n = 194 (72%) in group, n = 51 (19%) in , and n = 25 (9%) in was available for 182 (67.4%) patients and 112 (62%) harbored pathogenetic mutations. group included more frequently patients with mutation, triple negative BC phenotype and more aggressive OC features. Median time between the two diagnosis was longer in group group (95 68 months, p = 0.021). A total of 105 OS events occurred, mostly related to OC (70.5%). We observed no differences in terms of OS according to the first cancer diagnosis. Age >50 years and advanced OC stage were negative independent prognostic factors for OS from the first diagnosis. In this cohort of patients with BC and OC, survival was dominated by OC related mortality. These data may be useful to plan and carry out adequate and timely surveillance programs and preventive measures.